Familiarize Yourself With Vilobelimab for COVID-19
June 2023
You’ll hear about the new COVID-19 treatment vilobelimab (Gohibic)...due to its emergency use authorization (EUA).
This med is a “complement inhibitor”...and it’s only authorized for treating COVID-19 in certain adults on mechanical ventilation or extracorporeal membrane oxygenation (ECMO).
Vilobelimab seems to reduce the risk of death when added to a steroid (dexamethasone, etc). But there are important limitations to the evidence supporting its use.
Get concise advice on drug therapy, plus unlimited access to CE
Hospital Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote